Medpace Holdings, Inc.
Financials
Valuation Metrics
Medpace Holdings, Inc.'s Market Cap is $17.10B. At end of 2025 it was $15.89B. Ranked #652 of 3,121 in US market (top 21%), #204 of 1,463 on NASDAQ (top 14%), #44 of 205 in Health Care Equipment & Services (top 21%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $17.10B | US#652/3,121 Sec#44/205 |
| Revenue | $2.78B | US#1,250/3,121 Sec#76/205 |
| Net Income | $492M | US#846/3,121 Sec#47/205 |
| Total Assets | $2.06B | US#2,071/3,121 Sec#104/205 |
| Net Assets | $434M | US#2,326/3,121 Sec#123/205 |
| Employees | 6,200 | US#1,105/3,121 Sec#82/205 |
| Value | ||
| P/E | 34.78x | US#1,705/3,121 Sec#71/205 |
| P/B | 39.40x | US#2,875/3,121 Sec#189/205 |
| PEG | 1.99x | US#1,043/3,121 Sec#49/205 |
| P/S | 6.14x | US#2,453/3,121 Sec#161/205 |
| EV/EBITDA | 27.75x | US#2,169/3,121 Sec#111/205 |
| FCF Yield | 4.29% | US#1,569/3,121 Sec#81/205 |
| Profitability | ||
| ROE | 113.29% | US#14/3,121 Sec#1/205 |
| ROA | 23.89% | US#71/3,121 Sec#3/205 |
| Op. Margin | 20.97% | US#854/3,121 Sec#24/205 |
| Revenue Growth | 24.67% | US#545/3,121 Sec#33/205 |
| Earnings Growth | 17.50% | US#908/3,121 Sec#48/205 |
| Financial Health | ||
| Debt Ratio | 374.16% | US#2,249/3,121 Sec#174/205 |
| Total Debt | $120M | US#2,391/3,121 Sec#134/205 |
| FCF | $734M | US#720/3,121 Sec#44/205 |
| Cash | $503M | US#1,073/3,121 Sec#61/205 |
| Current Ratio | 0.73x | US#2,569/3,121 Sec#200/205 |
| Net Debt/EBITDA | -0.64x | US#353/3,121 Sec#27/205 |
| Performance | ||
| 1Y Return | 22.02% | US#1,066/3,121 Sec#85/205 |
| 1M Return | 0.69% | US#548/3,121 Sec#66/205 |
| From 52W High | -9.65% | US#648/3,121 Sec#61/205 |
| 1Y MDD | -36.61% | US#1,839/3,121 Sec#102/205 |
| Trading | ||
| Volume | 166,976 shares | US#2,689/3,121 Sec#187/205 |
| Trading Value | $102M | US#738/3,121 Sec#65/205 |
| Per Share | ||
| EPS | $17.61 | US#111/3,121 Sec#11/205 |
| BPS | $15.54 | US#1,495/3,121 Sec#82/205 |
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.